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ABSTRACT: RNA technology has the potential to revolutionize
vaccination. However, the lack of clear structure−property
relationships in relevant biological models mean there is no clear
consensus on the chemical motifs necessary to improve RNA
delivery. In this work, we describe the synthesis of a series of
copolymers based on the self-hydrolyzing charge-reversible poly-
cation poly(dimethylaminoethyl acrylate) (pDMAEA), varying the
lipophilicity of the additional co-monomers. All copolymers
formed stable polyplexes, showing efficient complexation with
model nucleic acids from nitrogen/phosphate (N/P) ratios of N/P
= 5, with more hydrophobic complexes exhibiting slower charge reversal and disassembly compared to hydrophilic analogues. The
more hydrophobic copolymers outperformed hydrophilic versions, homopolymer controls and the reference standard polymer
(polyethylenimine), in transfection assays on 2D cell monolayers, albeit with significantly higher toxicities. Similarly, hydrophobic
derivatives displayed up to a 4-fold higher efficacy in terms of the numbers of cells expressing green fluorescent protein (GFP+) cells
in ex vivo human skin (10%) compared to free RNA (2%), attributed to transfection enrichment in epithelial cells. In contrast, in a
mouse model, we observed the reverse trend in terms of RNA transfection, with no observable protein production in more
hydrophobic analogues, whereas hydrophilic copolymers induced the highest transfection in vivo. Overall, our results suggest an
important relationship between the vector lipophilicity and RNA transfection in vaccine settings, with polymer biocompatibility
potentially a key parameter in effective in vivo protein production.
■ INTRODUCTION
Since the advent of in vitro transcription, mRNA (mRNA)
therapeutics have evolved into a flexible platform, capable of
artificially introducing or replacing specific proteins for
vaccination and therapeutic applications.1,2 The nonintegrating
nature of mRNA means that this technology can be easily
inserted into current clinical practice, without the long-term
safety risks posed with genome altering DNA alternatives.3−5
As such, several mRNA therapies have undergone, or are
currently undergoing clinical trials,6−8 while their manufactur-
ability is currently under investigation.9,10
The activity of RNA therapeutics relies on the efficient
delivery of the nucleic acid to the cytosol of the cells at the
target site, where it is translated into the active protein.
However, naked mRNA suffers from quick pharmacokinetic
clearance, poor cellular association and facile degradation,
significantly reducing the cytosolic dose and thus its
therapeutic activity.11 Given these drawbacks, numerous
nonviral delivery strategies such as liposomes12,13 and cationic
polymers14−19 which protect, improve pharmacokinetics and
aid cytosolic delivery of RNA, have been developed.
Strategies exploiting polycations operate by condensing the
nucleic acid through electrostatic complexation, forming 100−
200 nm polyelectrolyte nanoparticles termed polyplexes that
facilitate translocation of the genetic material into the cell.
Most nonviral cationic vectors are designed to complex
strongly to nucleic acids to afford protection in transit through
the body; however for translation, RNA must also be released
from the vector and interact with the cellular protein
machinery. Vectors can achieve this release process either by
introducing chemistries that break the polycationic chain in
response to endogenous stimuli (GSH, ROS, pH, enzymes)20
or through self-immolative charge alteration, which terminates
the electrostatic attraction between a vector and nucleic acid.21
Although many of the above endogenous stimuli can be useful
for delivery in specific disease states, self-immolative pathways
for charge reversal may offer a route for mRNA release in the
absence of any specific stimuli.
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At present, there are few examples of gene delivery using
self-immolative charge altering vectors. Notable examples
include enhanced mRNA delivery utilizing an oligo-
(carbonate-β−α-amino ester), which rapidly degrades into a
neutral diketopiperazine through an ester−amide cyclization
reaction, releasing the mRNA.22 Another key example is the
self-catalyzed hydrolysis of poly(dimethylaminoethyl) acrylate
(pDMAEA), which degrades from a polycation into poly-
anionic poly(acrylic acid) (pAA) in the presence of water
releasing dimethylaminoethanol (DMAE).23−31 From a gene
delivery perspective, this delivery system will efficiently
condense nucleic acids in their positively charged state and
then hydrolyze, charge invert, repell, and release the genetic
cargo using a single material. Systems based on the charge-
reversing nature of pDMAEA have already been utilized to
deliver siRNA29,31,32 and pDNA;25 however, no studies have
yet examined its potential for mRNA delivery.
It has recently been reported that the introduction of
hydrophilic co-monomers, such as poly(dimethylaminoethyl)
hydroxymethacrylate,33 or the spacing of DMAEA units within
the chain with nonhydrolyzing DMAEMA can vary the rate
and final degree of hydrolysis.29 Furthermore, to date, most
previous examples show a pH-independent hydrolysis
mechanism, with few reports showing this can be overcome
by hindering the interaction with hydroxide ions.34 This was
achieved by incorporating anionic moieties along the chain;
however, such systems would not be beneficial for gene
delivery, as they are not net positively charged. Accordingly, we
report here a systematic mechanistic study utilizing a library of
pDMAEA copolymers, varying the co-monomer lipophilicity
to study (a) the effect on hydrolysis rate, (b) if this effects the
pH-independent mechanism, and (c) the implications of the
co-monomer and charge reversal on mRNA delivery from the
perspective of vaccination.
We designed and synthesized a series of pDMAEA
copolymers containing varying degrees of a hydrophobic co-
monomer, butyl acrylate (BA), and a hydrophilic co-monomer,
2-hydroxyethyl acrylate (HEA), as well as pDMAEA and
pDMAEMA (nonhydrolyzing) controls. Hydrolysis was
monitored at pH 5.5, 7.4, and 10.1 over 5 days using 1H
NMR spectroscopy. All copolymers were formulated into
polyplexes with model nucleic acids, and the particle sizes and
zeta-potentials were monitored over 7 days, as the polymers
charge inverted. Finally, we evaluated the potential for the
vectors to deliver mRNA in a vaccine setting, utilizing a 2D cell
culture, in ex vivo skin explants and a murine in vivo model.
■ MATERIALS AND METHODS
Materials. 2-Hydroxyethyl acrylate (HEA, 96%), butyl acrylate
(BA, > 99%), 2-(dimethylamino)ethyl acrylate (DMAEA, > 98%),
and 2-(dimethylamino)ethyl methacrylate (DMAEMA, 98%) were
obtained from Sigma-Aldrich and the inhibitor removed by passing
the monomers through a column of aluminum oxide. Deuterium
oxide (99.9% D atom), DMSO-d6 (99.5% D atom), sodium
deuteroxide (40 wt %, 99.5% D atom) and deuterium chloride (35
wt %, 99% D atom) were obtained from Sigma-Aldrich and used for
1H NMR spectroscopy. Thermal initiators 4,4′-azobis(4-cyanovaleric
acid) (ACVA, > 98%) and 1,1′-azobis(1-cyclohexanecarbonitrile)
(VA-088, 98%) were purchased from Sigma-Aldrich and used as-
received. Reversible addition−fragmentation chain-transfer (RAFT)
agents, (4-cyano pentanoic acid)yl ethyl trithiocarbonate (CEPTC),
and 2-((butylthio)-carbonothioyl) thio propanoic acid (PABTC)
were synthesized as previously reported.35,36 Ultrapure calf thymus
DNA (∼2000 bp) was purchased from ThermoFisher Scientific, and
fLuc pDNA (7047 bp), fLuc VEEV saRNA (9382 nt), and eGFP
VEEV saRNA (8449 nt) were prepared as described below.
Defibrinated sheep blood was purchased from Oxoid, UK. Solvents
and other reagents were acquired from commercial sources and used
as-received unless stated otherwise.
Methods. Instrumentation and Analysis. NMR Spectroscopy. 1H
and 13C NMR spectra were recorded on a Bruker DPX-400
spectrometer using deuterated solvent (Materials).
Size Exclusion Chromatography. SEC analysis was performed
using a Polymer Laboratories PL-50 instrument fitted with a
differential refractive index detector. The system was equipped with
2× PLgel Mixed D columns (300 × 7.5 mm) and a PLgel 5 μm guard
column. The eluent used was 0.1% LiBr in dimethylformamide
(DMF). Samples were eluted at 1 mL min−1 with the column oven
heating to 50 °C. PMMA standards (Agilent EasyVials) were used for
conventional calibration between 500−955550 g mol−1. Experimental
molar mass (Mn,SEC) and dispersity (Đ) values of synthesized
polymers were determined by using Cirrus GPC software.
Theoretical Molar Mass Calculation. Calculation of the













where [M]0 and [CTA]0 are the initial concentrations (in mol dm
−3)
of the monomer and chain transfer agent, respectively; p is the
monomer conversion as determined by 1H NMR spectroscopy; and
MM and MCTA are the molar masses (g mol
−1) of the monomer and
chain transfer agent, respectively.
Polymer Synthesis and Characterization. Polymer Synthesis.
Polymers were synthesized using the following procedure, utilizing the
conditions described in Table S1. RAFT agent (either PABTC or
CEPTC), monomer (DMAEA, HEA and BEA in the appropriate
ratios), and ACVA were dissolved in 1,4-dioxane. The polymerization
vessel was sealed with a septum, and purged with nitrogen for 20 min.
The vessel was immersed in an oil bath preheated to 70 °C until the
polymerization reached 80−90% monomer conversion as determined
by 1H NMR spectroscopy. Once complete, the polymerization
solution was removed from the oil bath, cooled to room temperature,
and exposed to oxygen to quench the polymerization. Polymers were
purified by precipitation twice in hexane or diethyl ether. The
precipitated polymer was dissolved in dichloromethane (DCM), with
DCM removed in vacuo.
NMR Hydrolysis Assays. Hydrolysis studies to evaluate the kinetics
of charge reversal were performed by 1H NMR spectroscopy. Studies
were performed at pH 5.5, 7.4, and 10.1 using acetate, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and carbo-
nate buffers in D2O, respectively. Buffers were adjusted using NaOD
or DCl. P1−P8 (20 mg) were dissolved in each buffer (0.6 mL).
Notably, as we prepared solutions with D2O, a correction factor (pD
= pH + 0.41) was applied to account for the difference in acidity
between H2O and D2O. A crystal of 1,3,5-trioxane was added to the
tube as an external reference. 1H NMR spectra were recorded at 24 h
intervals for 5 days. Hydrolysis percentages were calculated based on
the integrals at 3.7 (OCH2 on DMAE residues) and 4.2 ppm (OCH2
on pDMAEA residues). In some cases where peaks were overlapping,
the proton resonances arising from the CH3 in butyl acrylate at 0.8
ppm were integrated and back-calculated based on the target
monomer composition. Furthermore, the hydrophobic derivatives
were not fully soluble throughout the study; hence, the DMAE signals
at 3.7 ppm were integrated against the 1,3,5-trioxane signals, and at
the end of the study, DCl was added to fully solubilize the polymer to
calculate the % hydrolysis for each time point.
pH Titration. pH titrations were carried out as previously
described.16 Briefly, 1 mg of polymer (P1−P8 and polyethylenimine
(PEI)) was dissolved in 30 mL of NaCl (0.1 M), and the pH was
adjusted to 3 through the addition of HCl (0.1 M). The polymer
solution was titrated with NaOH (0.1 M), and the pH value of
solution was measured until a pH of 5 was achieved.
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Nucleic Acid Synthesis. RNA In Vitro Transcription and
Purification. saRNA was prepared as previously described.16 Briefly,
self-amplifying RNA encoding the replicase derived from the
Venezuelan Equine Encephalitis Virus (VEEV) and either firefly
luciferase (fLuc) or enhanced green fluorescent protein (eGFP) was
produced using in vitro transcription. pDNA was transformed into
Escherichia coli, cultured in 100 mL of lysogeny broth (LB) with 100
μg/mL carbenicillin (Sigma-Aldrich, UK), and isolated using a
Plasmid Plus MaxiPrep kit (QIAGEN, UK). The concentration and
purity of pDNA was measured on a NanoDrop One (ThermoFisher,
UK) and subsequently linearized using MluI for 3 h at 37 °C. For in
vitro transfections, capped RNA was synthesized using 1 μg of a
linearized DNA template in a mMessage mMachine (Ambion, UK)
and purified using a MEGAClear column (Ambion, UK) according to
the manufacturer’s protocol. RNA for ex vivo experiments was
prepared as previously described.37 Uncapped RNA transcripts were
synthesized using 1 μg of linearized DNA in a MEGAScript reaction
(Ambion, UK) according to the manufacturer’s protocol. Transcripts
were then purified by overnight LiCl precipitation at −20°C, pelleted
by centrifugation at 14000 rpm for 20 min at 4 °C, washed 1× with
70% EtOH, centrifuged for 14000 rpm for 5 min at 4°C, and then
resuspended in UltraPure H2O (Ambion, UK). Purified transcripts
were then capped using a ScriptCap Cap 1 capping system kit
(CellScript, Madison, WI, USA) according to the manufacturer’s
protocol. Capped transcripts were then purified by LiCl precipitation
as detailed above, resuspended in UltraPure H2O, and stored at
−80°C until further use.
Polyplex Formulation. Polymer Nucleic Acid Complexation.
Stock solutions of the polymer and nucleic acid were prepared at
double the concentration required in the polyplexes in the HEPES
buffer (20 mM, pH 7.4) and 5 wt % glucose. Complexes were
prepared by mixing the solutions 1:1 to produce the desired N/P
ratio. Polyplexes were stirred at 25 °C for 30 min to allow formation.
For size and zeta-potential studies, polyplexes were prepared with calf
thymus DNA and with fLuc encoding pDNA for gel electrophoresis.
For in vitro transfection studies, stock solutions of the polymers were
prepared at a concentration of 5 mg/mL in HEPES butter (20 mM,
pH 7.4) and 5 wt % glucose. The polymer solution was added to the
RNA solution at a ratio of 4:1 (v/v) to yield a final RNA
concentration of 0.001 mg/mL such that 100 ng was added to each
well of a 96-well plate.
Particle Size and Zeta-Potential Analysis. The polyplex size and
zeta-potential analysis were prepared using a previously reported
procedure16 at N/P ratios of 0.5, 1, 2, 5, 10, 20, and 50 with the
polymer fixed at 0.1 mg mL−1. The calf thymus DNA concentration
varied for each N/P ratio. Size measurements were performed directly
with the prepared polyplex solutions. For zeta-potential measure-
ments, polyplex solutions were diluted 1:1 with 10 mM NaCl (aq).
Measurements were performed as described in Instrumentation and
Analysis. For hydrolysis studies, polyplexes were measured at 24 h
intervals and stored at 37 °C between measurements.
Gel Electrophoresis. Gel electrophoresis experiments were
performed following a reported protocol.16 Briefly, polyplexes for
the gel retardation assay were prepared with a fixed DNA
concentration of 200 ng mL−1 with polymer concentrations varied
for each N/P ratio. Then, 20 μL of polyplex and 4 μL of loading dye
(-SDS, 6×) were loaded onto a 1% agarose gel + GelRed in Tris-
acetate-EDTA 1× (TAE) buffer, subjected to electrophoresis for 40
min at 100 V, and visualized with an UV illuminator.
In Vitro Studies. Hemolysis. Defibrinated sheep blood (7.5 mL)
was centrifuged at 4500 g for 10 min at room temperature to collect
erythrocytes. The supernatant and pellet were separated, and the
supernatant was replaced with 5 mL of fresh phosphate-buffered
saline (PBS) and the pellet resuspended. This was repeated until the
supernatant was completely colorless. Then, the suspension was
diluted 10-fold in PBS. Polyplexes were prepared with polymers P1−
P8 and PEI at N/P ratios of 0.5, 5, and 50 in the HEPES buffer (0.02
M) with calf thymus DNA (0.1 mg mL−1). Then, 20 μL of each
polyplex was then diluted with 380 μL of erythrocyte resuspension in
1.5 mL Eppendorf tubes such that the final concentration of DNA was
50 μg mL−1, 5 μg mL−1, and 0.5 μg mL−1. The controls of PBS and
HEPES (negative) and a 1% Triton-X (positive) PBS solution were
also prepared and treated as above. Erythrocyte polyplex mixtures
were then incubated at 37 °C for 3 h and subsequently separated by
centrifugation at 4500 g for 5 min. Then, 200 μL of the supernatant
from each tube was removed and transferred to a clear 96-well plate,
and the absorbance was read at 540 nm using a TECAN SPARK
multimode plate reader. The average PBS negative control value was
subtracted from nanoparticle values and divided by the average
Triton-X positive control value to obtain the % hemolysis. Errors were
determined using the standard deviation of the three replicates.
Cytotoxicity Assay. Cells were transfected with polyplexes
prepared with luciferase encoding self-amplifying RNA (saRNA)
and P1−P8 at N/P ratios of 2, 10, and 50. Then, at 24 h post-
treatment, each well was treated with 20 μL of CellTiterBlue reagent
(Promega, UK) and subsequently incubated for 1 h. The absorbance
of each well was determined using a FLUOstar Omega plate reader
(BMG LABTECH, UK) and normalized to the untreated control.
In Vitro Transfection of saRNA Polyplexes. In vitro transfection
experiments were performed using a previously reported procedure.16
Briefly, transfections were performed in HEK293T.17 cells (ATCC,
USA) that were maintained in culture in complete Dulbecco’s
Modified Eagle’s medium (cDMEM) (Gibco, ThermoFisher, UK)
containing 10% (v/v) fetal calf serum (FCS), 5 mg mL−1 L-glutamine,
and 5 mg mL−1 penicillin and streptomycin (ThermoFisher, UK).
Cells were plated at a density of 50000 cells/well in a 96-well plate 24
h prior to transfection. At the time of transfection, the media was
completely removed and replaced by 50 μL of transfection media
(DMEM with 5 mg mL−1 L-glutamine). Then, 100 μL of the polyplex
solution was added to each well and incubated for 4 h. Then, the
media was replaced with cDMEM, and the cells were allowed to
culture for 24 h, at which time 50 μL of media was removed, and 50
μL of the ONE-Glo D-luciferin substrate (Promega, UK) was added
and mixed well by pipetting. The total volume was transferred to a
white 96-well plate (Costar, UK) and analyzed on a FLUOstar Omega
plate reader (BMG LABTECH, UK).
Ex Vivo Studies. Flow Cytometry Analysis of eGFP Expression in
Human Skin Explants. The transfection of cells in human skin
explants and the flow cytometry analysis were performed as previously
described.16 Surgically resected specimens of human skin tissue were
collected at Charing Cross Hospital, Imperial NHS Trust, London,
UK. All tissues were collected after receiving signed informed consent
from patients, under protocols approved by the Local Research Ethics
Committee (MED_RS_11_014). The tissue was obtained from
patients undergoing elective abdominoplasty or mastectomy surgeries
and was processed as previously described.37 Upon arrival in the
laboratory, the subcutaneous layer of fat was removed, and the tissue
was excised into 1 cm2 pieces. Explants were incubated at 37 °C with
5% CO2 in 12-well plates with cDMEM, which was replaced daily.
Explants were injected intradermally (ID) using a micro-fine Demi 0.3
mL syringe (Becton Dickinson, UK) with 5 μg of eGFP saRNA
polyplexes. After 72 h, explants were digested into single cell
suspensions by incubating in 2 mL of DMEM supplemented with 1
mg/mL collagenase P (Sigma, UK) and 5 mg/mL Dispase II (Sigma,
UK) for 4 h at 37 °C on a rotational shaker. Digests were then filtered
through a 70 μm cell strainer and centrifuged at 1750 rpm for 5 min.
Cells were then resuspended in FACS buffer (PBS + 2.5% FCS) and
stained with a Fixable Aqua Live/Dead Cell stain (ThermoFisher,
UK) diluted at 1:400 in FACS buffer for 20 min. Cells were then
washed and stained with a panel of antibodies to identify each cell
type for 30 min. The antibody panel included CD3-V450 (BioLegend,
UK), CD14-Qdot605 (BioLegend, UK), CD19-BV650 (BioLegend,
UK), CD56-BV711 (BioLegend, UK), CD1a-PerCP-eFluor710
(BioLegend, UK), CD11c-PE (BioLegend, UK), CD90-PE-Cy7
(BioLegend, UK), and CD45-AF700 (BioLegend, UK). Cells were
then fixed in 1.5% paraformaldehyde and refrigerated until the flow
cytometry analysis was conducted. Samples were analyzed on a
LSRFortessa (BD Biosciences, UK) with FACSDiva software (BD
Biosciences, UK) with 100000 acquired cell events. Gating and
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analysis was performed in FlowJo Version 10 (FlowJo LLC, Oregon,
USA).
In Vivo Studies. In Vivo fLuc Expression. In vivo fLuc saRNA
transfection experiments were performed as previously described.19
All animals were handled in accordance with the UK Home Office
Animals Scientific Procedures Act 1986 and with an internal ethics
board and UK government approved project (P63FE629C) and
personal license (IC37CBB8F). Food and water were supplied ad
libitum. Female BALB/c mice (Charles River, UK) 6−8 weeks of age
were placed into groups (n = 5) and housed in a fully acclimatized
room. In vivo imaging was performed as previously described. Mice
were injected either intramuscularly in both hind legs or intradermally
with 5 μg of fLuc saRNA complexed with P1−P8 or PEI in a total
volume of 50 μL. After 7 days, the mice were injected intra-
peritoneally (IP) with 100 μL of XenoLight RediJect D-luciferin
substrate (PerkinElmer, UK) and allowed to rest for 10 min. Mice
were then anesthetized using isoflurane and imaged on an In Vivo
Imaging System (IVIS) FX Pro (Kodak Co., Rochester, NY, USA)
equipped with Molecular Imaging software version 5.0 (Carestream
Health, USA) for 2 min. The signal from each injection site was
quantified using Molecular Imaging software and expressed as relative
light units (p/s).
Statistical Analysis. Plots and statistics were performed using
GraphPad Prism, version 8. Significant differences were identified
using either multiple t tests adjusted for multiple comparisons or one-
way ANOVA with multiple comparisons.
■ RESULTS AND DISCUSSION
Polymer Synthesis and Characterization. A library of
eight cationic polymers (P1−P8) were synthesized using
RAFT polymerization. Six (P1−P6) of these were prepared
with 50 mol % charge-reversible monomer DMAEA, while the
lipophilicity of the other 50 mol % was varied by increasing
and decreasing (in 10 mol % increments) the quantity of HEA
and BA, respectively (Scheme 1), with a total DPtarget = 50.
Furthermore, pDMAEA25 (P7) and pDMAEMA25 (P8)
homopolymers were prepared as fully hydrolyzing and
nonhydrolyzing controls respectively, with the same cationic
content (25 units) as P1−P6. Acrylate polymerizations were
performed with the RAFT agent PABTC at 70 °C using
thermal initiation with ACVA, while methacrylate polymer-
izations performed with RAFT agent CPAETC at 90 °C with
Scheme 1. Schematic Representation for RAFT Polymerization and Monomer Composition of Homopolymers and
Copolymers P1−P8a
aInset shows the charge reversal process.
Table 1. Structure and Characterization of the Polymers (P1−P8) Synthesized in This Study
polymer structure Mn,th (g mol
−1)a Mn,SEC (g mol
−1)b Đb
P1 pDMAEA25-co-BA25 7000 3300 1.16
P2 pDMAEA25-co-BA20-co-HEA5 6950 5400 1.22
P3 pDMAEA25-co-BA15-co-HEA10 6900 7000 1.18
P4 pDMAEA25-co-BA10-co-HEA15 6850 7300 1.21
P5 pDMAEA25-co-BA5-co-HEA20 6800 7800 1.24
P6 pDMAEA25-co-HEA25 6700 10300 1.15
P7 pDMAEA25 3800 3100 1.21
P8 pDMAEMA25 4300 5000 1.22
aCalculated using eq 1. bDetermined using DMF-SEC.
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VA-088. Full conditions can be found in the Supporting
Information (Table S1). 1H NMR spectroscopy revealed the
synthesized polymers had the targeted co-monomer composi-
tion, while DMF-SEC analysis revealed narrow (Đ < 1.25) and
monomodal chromatograms (Table 1, Figure S1, Figure S2).
Some deviation between experimental and theoretical molar
Figure 1. (A) Representative 1H NMR spectrum illustrating the release of DMAE from pDMAEA homopolymer P7 over 5 days. (B) Hydrolysis
kinetics derived from 1H NMR spectra of P1−P8 over 5 days in D2O at pH 5.5 (red line), 7.4 (blue line), and 10.1 (green line). (C) pH titration of
P1−8, PEI, and 0.1 M NaCl from pH 3 to pH 11, titrated with 0.1 M NaOH (aq). (D) Schematic representation of the partial hydrolysis of
pDMAEA copolymers containing either hydrophilic or hydrophobic co-monomers, leading to pH-dependent hydrolysis, due to the hydroxide
access for more hydrophilic pDMAEA analogues.
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masses was observed, this was more apparent for copolymers
with higher HEA mol % likely due to their greater swelling
during SEC analysis. The statistical monomer distribution of
DMAEA, BA, and HEA ternary copolymers was confirmed
through a kinetic polymerization study performed on a mixture
containing 33% of each monomer. 1H NMR spectra of samples
withdrawn periodically through the polymerization revealed
identical polymerization kinetics for each co-monomer (Figure
S3), suggesting identical reactivity ratios.
Chain Lipophilicity Induces pH Dependency on
Charge Reversal. Previous reports studying the charge
reversal of pDMAEA into pAA have identified a pH-
independent self-catalyzed hydrolysis mechanism. However,
most of these studies utilize block copolymers,32 homopol-
ymers,24,25,28,31 or statistical copolymers containing co-
monomers with complementary functionalities such that
there is limited spacing between basic residues within the
chain.29 Given this, we were interested in identifying if the
relative lipophilicity of the copolymers impacted the rate of
pDMAEA hydrolysis and its pH-independent mechanism.
Hydrolysis kinetics of DMAEA side chains in P1−P8 was
determined by recording daily 1H NMR spectra at pH 5.5, 7.4,
and 10.1, monitoring the reduction and increase of integrals of
the signals at 4.2 ppm (CH2 next to ester in polymer) and 3.7
ppm (CH2 next to alcohol in DMAE), respectively (Figure 1A
and Figure S4). Where copolymers were sparingly soluble at
the beginning of the study, a soluble external reference of 1,3,5-
trioxane was added to the NMR tubes, and the integrals were
back-calculated at the end of the study, at which point
Figure 2. (A) DLS traces of polyplexes comprising P1−P8 (0.1 mg mL−1) and calf thymus DNA at N/P = 10 measured at 37 °C. Evolution of (B)
particle size and (C) zeta-potential of polyplexes comprising P1−P8 (0.1 mg mL−1) and calf thymus DNA at N/P = 10 measured at 37 °C
measured after 24 (blue), 48 (green), 72 (purple), 96 (orange), 120 (black), and 168 h (red). (D) Evolution of the derived scattering intensity/
count rate of polyplexes, normalized to the initial measurement at t = 0 h, comprising P1−P8 (0.1 mg mL−1) and calf thymus DNA at N/P = 10
measured at 37 °C over 7 days. (E) Schematic representation of nucleic acid binding, charge reversal, and subsequent nucleic acid release.
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deuterium chloride was added to protonate and solubilize the
copolymers to quantify the percentage hydrolysis.
P1−P6 exhibited comparable hydrolysis rates, reaching ∼50
and 20−30% hydrolysis at pH 7.4 and 5.5 respectively, over 5
days at 37 °C. In contrast, at pH 10.1 the more hydrophobic
copolymers (P1 and P2) hydrolyzed significantly slower rates
(∼40% over 5 days) than the more hydrophilic derivatives
(∼60% over 5 days), with the kinetic profiles revealing a trend
of faster hydrolysis with increasing hydrophilicity (Figure 1B).
We hypothesize that the slower hydrolysis in P1 and P2 at pH
10.1 may be due to the DMAEA residues being deprotonated
at pH 10.1, causing these analogues to be sparingly soluble in
the early stages of hydrolysis. However, once a significant
portion is hydrolyzed, the resulting acrylic acid residues are
deprotonated at this pH, improving the solubility, which may
explain the increased hydrolysis rate observed after 72 h.
Consistent with the literature, the pDMAEA homopolymer P7
showed almost identical hydrolysis rates at all three pH values,
reaching 60% over the course of the experiment, while the
nonhydrolyzing pDMAEMA homopolymer P8 did not show
any significant signs of hydrolysis.
Interestingly, we observed that the difference in the
hydrolysis rate and the final percentage of hydrolysis between
pH 5.5 and pH 10.1 increased significantly with the
hydrophilic co-monomer composition. For instance, after 5
days, P1 reached 30, 37, and 45% hydrolysis at pH 5.5, 7.4, and
10.2, respectively, which represented a 15% difference between
acidic and basic conditions. In contrast, P6 was hydrolyzed to
extents of 20, 50, and 65%, a difference of 45% under the same
treatment conditions (Figure 1B). While DMAEA homopol-
ymers typically exhibit pH-independent hydrolysis, here we
demonstrate a pH-dependent hydrolysis controlled by the
hydrophobicity of the co-monomer. We anticipate this
behavior may originate depending on the solubility of the
zwitterionic complex, which is formed as hydrolysis approaches
50%. In this state, the chains will be partially positive and
partially negative, collapsing due to the intramolecular
electrostatic attraction. The more hydrophobic derivatives
will be less prone to charge reversal due to the poor hydration
of these collapsed chains, slowing their hydrolysis (Figure 1D).
This behavior may be important in gene delivery, leading to
the potential of a pH-dependent controlled release of nucleic
acids, or in anatomies and cellular compartments with
nonphysiological pH levels.
Lipophilic Polyplexes Charge Invert Slower than
Hydrophilic Derivatives. Prior to formulating the synthe-
sized polymers with nucleic acids, we investigated the buffering
capacity of P1−P8 by titrating dilute polymer solutions with
0.1 M NaOH from pH 2.5 to pH 11. P1−P7 displayed similar
titration curves, with two observable pKa values, one at ∼ pH 5
and the other at ∼ pH 10. These were compared to PEI, the
reference standard in gene transfection, and P8, the
pDMAEMA homopolymer (Figure 1C). Both showed poorer
buffering with less defined pKa values, likely due to the density
of basic residues minimizing the propensity of these analogues
for successive protonation events.
Polyplex formulations were optimized using model nucleic
acids, either with calf thymus DNA or luciferase-encoding
plasmid DNA. Particle size, zeta-potential measurements, and
gel-retardation assays were performed on polyplexes at N/P
ratios of 0.5, 1, 2, 5, 10, 20, and 50. Stable complexes,
displaying narrow particle size distributions (PDi < 0.3),
positive zeta-potentials above 20 mV, and full DNA-binding
abilities were observed above N/P = 5 (Figure S5). All
polymers yielded polyplexes of similar sizes, exhibiting average
diameters between 120 to 200 nm (Figure 2A). The particle
size (Figure 2B) and zeta-potentials (Figure 2C) of polyplexes
formulated at N/P = 10 utilizing the charge-reversible
polymers (P1−P7) evolved steadily over 1 week as hydrolysis
progressed. Interestingly, instead of decreasing in size as
polymers in polyplexes hydrolyzed, the polyplex diameters
increased from ∼150 nm to over 1000 nm (Figure 2B).
However, at this time point, the scattering intensity of the
solutions rapidly decreases (Figure 2D), indicating partial or
full disassembly of the polyplex, but the increase in particle
size, visible via DLS (Figure 2B), is likely due to a few
aggregated particles when the zeta potentials reach ∼0 mV,
skewing the light scattering analysis. The charge-reversible
nature of P1−P7 was evidenced by the steadily decreasing zeta-
potentials, decreasing from positive (∼30 mV) to negative (−6
mV) as the cationic DMAEA units hydrolyzed to anionic
acrylic acid residues (Figure 2C). The nonhydrolyzing
pDMAEMA homopolymer P8 exhibited some aggregation,
increasing from 110 to 145 nm diameters between 1 and 7
days, while the zeta-potentials showed minimal change (Figure
2B). The zeta-potentials and scattering intensity of the
hydrophobic copolymers decreased significantly slower than
hydrophilic analogues, likely due to the lower hydration
potential of these complexes, slowing the self-catalyzed
hydrolysis process. These results indicate that polyplexes
formulated with self-hydrolyzing analogues should be effective
at releasing nucleic acids, and the particles themselves will
dissociate, potentially avoiding bioaccumulation.
Hydrophobic Polyplexes Are the Most Cytotoxic yet
Induce the Highest Protein Expression In Vitro. We
assessed the membrane interactions of polyplexes derived from
our library of polymers by evaluating their propensity to lyse
erythrocytes (hemolysis, Figure 3A). Polyplexes derived from
P1−P8 and PEI were formulated at N/P = 0.5, 5, and 50.
Their hemolytic activity was compared to Triton-X (positive
control), HEPES buffer (vehicle control), free DNA and PBS
(negative control). The observable increasing trend in
hemolytic activity with increasing N/P ratios is likely due to
the higher concentration of free polymer not residing in the
polyplex. Previous studies have indicated that, although the
nominal N/P ratio in the solution typically exceeds 10, the
actual N/P ratio within the complex usually does not exceed 2;
thus, substantially more free polymer is present at high N/P
ratios.38,39 At N/P = 50, a stepwise increase in the hemolytic
activity was observable with more hydrophobic analogues,
starting with negligible hemolysis in P6 polyplexes and rising to
97% hemolysis, which is almost identical to the positive
control, in P1 polyplexes (Figure 3A). It is well documented
that polycations incorporating hydrophobic residues are
exceptionally membrane active due to their attraction to the
phospholipid bilayer and disruptive hydrophobic interactions.
The hemolytic activity has also been a key marker for high
endosomal escape efficiencies and thus may give insight into
the mechanisms of RNA delivery for these polymers.40
Following this, the in vitro transfection efficiency and
cytotoxicity of polyplexes comprising fLuc-encoding saRNA
and polymers P1−P8 at N/P ratios of 2, 10, and 50 in
HEK293T cells after 24 h of incubation were also assessed
(Figure 3B). From a vaccination perspective, saRNA poses
significant advantages over conventional mRNA, as these
constructs self-replicate upon their arrival in the cytoplasm,
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substantially reducing the required dose for effective
immunization. The saRNA complexes displayed particle sizes
similar to those prepared with model DNA for the hydrolysis
studies above. However, saRNA polyplexes exhibited more
negative zeta potentials than DNA analogues, potentially
attributed to the poorer condensation of the larger nucleic acid
with relatively low molar mass polycations (Figure S6). This is
consistent with a previous report indicating complexes with
high molar mass polycations at high N/P ratios display positive
zeta potentials, while low molar mass analogues showed
negative potentials.19 As in the case of the hemolytic activity,
the polyplexes derived from all of the synthesized polymers at
higher N/P ratios were significantly more cytotoxic, again
likely due to the higher concentration of noncomplexed
polymer. Interestingly, P6 and P7, the most hydrophilic
derivatives, and the pDMAEA homopolymer were the least
cytotoxic at any N/P ratio (Figure 3B). We anticipate that the
absence of BA units and the faster hydrolysis may account for
the higher compatibility, which would negate any membrane
damaging properties. Analogues with more BA units displayed
significantly higher cytotoxicities (P1 > P2 > P3 > P4), likely
arising from stronger membrane disruption at all three N/P
ratios,41 in accordance with the hemolytic activity data.
Using the same fLuc reporter saRNA polyplexes at N/P
ratios of 2, 10 and 50, in vitro transfection was assessed in
HEK293T cells after 24 h of incubation, comparing these to an
optimized PEI formulation (N/P = 10) as a positive control
(Figure 3C). The more hydrophilic analogues P3−P6
displayed similar or lower transfection efficiencies than PEI
(∼6.5 × 104 RLU) at all three N/P ratios. Remarkably, P1 and
P2, the copolymers containing the highest BA composition,
exhibited significantly higher transfection efficiencies than PEI
at N/P = 2 (∼24-fold and ∼5.5-fold higher for P1 and P2,
respectively) and N/P = 10 (∼11-fold and ∼20-fold for P1 and
P2, respectively, Figure 3A). Coupled to the previous
cytotoxicity data, the lower transfection efficiencies at higher
N/P ratios are likely a product of the reduced number of cells
available for transfection. Nonetheless, the lower cell viabilities
for P1 and P2 at N/P = 2 and N/P = 10 indicate an even
higher transfection efficiency per cell compared to the
hydrophilic derivatives P3−P6, with only ∼60% of viable
cells still producing up to 24-fold higher luciferase in this cell
population compared to PEI formulations.
Hydrophobic Polyplexes Enhance the Number of
saRNA-Expressing Cells in Human Skin Explants. For
RNA vaccines to be easily incorporated into current clinical
practices, it has been posited that these would be administered
through traditional intramuscular or intradermal injections.42
We therefore examined the transfection efficiency of a subset
of the formulations tested in vitro in an ex vivo human skin
explant model (Figure 4A). Polymers P1, P3, P6, P7, and P8
were formulated into polyplexes with saRNA encoding for
green fluorescent protein (GFP) at N/P = 10. Nonformulated
RNA yielded expression in ∼2% of cells, which did not
significantly increase upon complexation with P3 (p = 0.92),
P6 (p > 0.99), P7 (p = 0.94), and P8 (p = 0.99). However,
formulations with P1, the most effective polymer in vitro,
showed a significant increase in GFP+ cells (∼11%) compared
to RNA alone (p = 0.022, Figure 4A). The numbers of GFP+
cells in these studies were similar to those in previous studies
with mannosylated PEI-saRNA complexes43 but were higher
than those with cationic lipid-saRNA formulations.37
Although many of the formulations did not increase the
percentage of GFP+ cells, skin is a complex tissue comprising
many cell types in their native tissue architecture. We therefore
sought to identify which cells were expressing the GFP.
Transfected skin explants were enzymatically homogenized,
and each cell type was labeled using a panel of fluorescently
labeled antibodies. Then, GFP+ cells were categorized by cell
type via flow cytometry (Figure 4B). We observed that the cell
phenotype in the skin used was predominantly epithelial
(∼60%), with leukocytes (∼8%) and fibroblasts (∼11%), and
dendritic (∼10%) with a much smaller proportion of
Langerhans cells (∼0.8%), natural killer (NK) cells (∼1%),
monocytes (∼3%), B cells (∼4%), and T cells (∼0.5%). In skin
treated with nonformulated RNA, the majority of GFP
expression was found in the commonly found epithelial cells,
leukocytes, and fibroblasts; however, some enrichment was
observed in NK cells, B cells, and Langerhans cells compared
to the cell composition of the skin (Figure 4B). The profile of
GFP+ cells was generally similar for skin treated with
polyplexes derived from the faster hydrolyzing hydrophilic
Figure 3. (A) Hemolytic activity of calf thymus DNA polyplexes
comprising P1−8 and PEI at N/P ratios of 50, 5, and 0.5, measured
after 3 h of incubation with erythrocytes collected from defibrinated
sheep blood. Cell viability as a function of (B) metabolic activity and
(C) luciferase expression in HEK 293T cells 24 h after transfection
with polyplexes formed of P1−P8 and fLuc saRNA compared to a
previously optimized PEI formulation (dotted gray line). Data are
represented as the mean ± standard deviation (n = 3).
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derivatives (P3, P6, and P7), with some enrichment in the
immune cell population. In contrast, skin treated with P1 and
P8, which both show slow or negligible charge reversal, had
similar expression profiles with a significantly higher expression
in epithelial cells, closely matching the resident skin cell
population (Figure 4B). From these observations, we can
conclude that P1 polyplexes at N/P = 10 enhance the number
of GFP+ cells in human skin explants due to an increase in the
expression from epithelial cells.
In Vivo Studies. Following the successful transfection of
2D cell monolayers and human skin explants mediated by our
charge-reversing polymers, we sought to evaluate their
potential in saRNA vaccination using an in vivo murine
model. Mice were injected intramuscularly on each leg with
polyplexes composed of charge-reversing polymers P1, P3, P6,
P7, and P8 with fLuc-encoding saRNA at N/P = 10. These
polymers were chosen such that we could examine the trends
in polymer hydrophobicity (P1, P3, and P6) and the effect of
charge reversal (P7 and P8) with a minimal number of animals.
The selected polymers were formulated for saRNA complex-
ation at N/P = 10 for consistency with in vitro and ex vivo skin
studies. The luminescence was monitored 7 days after injection
at the expected time point for peak expression (Figure 5A and
B). Charge-reversible formulations were compared to the
pDMAEMA nonhydrolyzing control P8 and an in vivo
optimized PEI formulation (jetPEI). In contrast to the data
obtained in the in vitro and ex vivo experiments, in the murine
model, the PEI formulation outperformed all polyplexes,
yielding an average luminescence of ∼5.0 × 105 RLU. Mice
administered with P1, P3, P6, P7, and P8 had a rather variable
luminescence, with no groups exhibiting RNA expression on
every injected leg. In contrast again to the in vitro and ex vivo
results above, P1 yielded no RNA expression across all five
animals, while mice treated with P6 polyplexes exhibited 7/10
positive legs with an average luminescence of ∼4 × 104,
roughly 10-fold lower than that of PEI (Figure 5A and B). It is
possible that the poor translation of P1 for in vitro to in vivo
protein expression arose due to the previously observed toxic
membrane interactions, causing local cell death proximal to the
injection site, or to local self-association/aggregation of the
more hydrophobic complexes in the protein-rich muscle
regions, of which both factors would have reduced transfection.
In contrast, polyplexes derived from P6, P7, and P8, which
were the least cytotoxic or membrane active, yielded the
highest efficacy in vivo, which may have been a consequence of
the high vascularization in muscle and rapid transport of
polyplexes following injection. In addition, animals treated
with the charge-reversible pDMAEA homopolymer (P7)
displayed similar luminescence values to those injected with
the nonhydrolyzing pDMAEMA control (P8). These data
perhaps indicate that the unpackaging of RNA from the
polyelectrolyte complexes is not the rate-limiting step in
transfection and expression of the target protein in vivo, at least
for these types of polymers injected into this anatomical site
(Figure 5A and B). There is always a trade-off between the
tight-binding of nucleic acids to afford colloidal stability in a
formulation and protection against nucleases following
injection and the ability to enter target cells and address the
translational machinery. In a site of high blood vessel and
Figure 4. (A) Proportion of GFP-positive cells from the total of live
cells in human skin explants. Data are represented as the mean ±
standard deviation (n = 3). Asterisks indicate relevant statistically
significant results (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). (B) Cell-
type profile in human skin explants and GFP+ cells after the injection
of polymer-saRNA formulations, as determined by flow cytometry.
Figure 5. (A) Quantitation of in vivo fLuc expression 7 days after IM
injection of PEI, P1, P3, P6, P7, and P8 saRNA (5 μg) polyplexes at
N/P = 10. Each circle represents one leg of one animal, and the bar
represents the mean ± SEM, n = 5. Asterisks indicate relevant
statistically significant results (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤
0.001). Note that P1, P3, P6, P7, and P8 are all significantly different
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protein content, such as a site following intramuscular
injection, the polyplexes have the potential to bind to many
other biomolecules prior to reaching a target cell. In addition,
the processing of RNA in vivo involves multiple competitive
binding interactions intracellularly, and these may have been
sufficient to the unpackaging of RNA from the complexes,
irrespective of whether the side-chains in the polycations were
hydrolyzing.
Finally, it should be noted that the polymers in this study
were designed as probes of transfection rather than materials to
be adopted in the clinic, as the acrylate-based chain is not
biodegradable. Nevertheless, as they are chemically well-
defined, the polymers could be used to test systematically
the effects of side-chain hydrophilicity and hydrophobicity in
conjunction with side-chain hydrolysis and charge-reversal in a
manner not possible for main-chain biodegradable polymers.
Our future studies will focus on further probing the
mechanisms by which the RNA polyplexes are transported
and unpackaged in as close to clinically relevant in vivo models
as possible.
■ CONCLUSIONS
In conclusion, we designed a systematic library of charge-
reversible polymeric gene delivery vectors, varying the relative
lipophilicity of copolymers based on the self-catalyzed
hydrolysis of pDMAEA. By spacing DMAEA units with
hydrophobic units, we were able to produce self-hydrolyzing
polymers with pH-dependent hydrolysis. In contrast, hydro-
philic residues diminished the pH dependency. Although there
was a negligible effect of polymer hydrophobicity on the charge
reversal at physiological pH levels, once formulated with
nucleic acids, the more hydrophobic derivatives exhibited
slower charge reversal, which is attributed to the reduced
hydration of the complex. Although all polymers displayed
similar buffering and nucleic acid binding capacities, the
stronger membrane activity of hydrophobic analogues likely
led to a 10- to 20-fold increase in the in vitro transfection
efficiency over PEI albeit with significant cytotoxicity.
Similarly, the most hydrophobic derivative P1 yielded a higher
percentage of transfected cells in human skin explants, ascribed
to transfection enrichment in epithelial cells. The superior
performance of the hydrophobic analogues, however, did not
translate in vivo, as they were outcompeted by the hydrophilic
derivatives. In general, we observed limited benefit in vitro or in
vivo with charge-reversible vectors (comparing pDMAEA and
pDMAEMA homopolymers), but these factors may be more
important from a toxicity and pharmacokinetic perspective.
This study clearly indicates the importance of lipophilicity of
nonviral vectors. We anticipate the results found here will help
direct future nonviral gene delivery vector design, with a
particular focus on RNA vaccines given the relevant data in
human skin and in vivo models.
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